In 2007, a hydrogel histrelin implant was approved for the treatment of children with central precocious puberty (CPP). Children with CPP commonly have reduced height potential due to premature closure of the epiphyseal growth plates from exposure to sex steroids. Gonadotropin-releasing hormone analog (GnRHa) treatment halts puberty and allows for improvement of adult height. A hydrogel implant...

Gonadotrophin-releasing hormone agonist (GnRHa)-induced ovulation after gonadotrophin ovarian stimulation is used to prevent ovarian hyperstimulation syndrome and multiple pregnancy in polyfollicular cycles. However, one of the major problems to be resolved is corpus luteum function after follicular maturation and ovulation by mid-cycle GnRHa administration. The present report investigated the ...

CONTEXT Gonadotropin-releasing hormone (GnRH) has been the standard test for diagnosing central precocious puberty. Because GnRH is no longer available, GnRH analogues (GnRHa) are now used. Random LH concentration, measured by the third-generation immunochemiluminometric assay, is a useful screening tool for central precocious puberty. However, GnRHa stimulation test should be considered, when ...

OBJECTIVE Congenital adrenal hyperplasia (CAH) can be complicated by central precocious puberty (CPP) in children, which may compromise final height. We aimed to evaluate the effect of gonadotropin-releasing hormone analog (GnRHa) therapy on growth in children with CAH. DESIGN Twelve children with CAH were enrolled in a follow-up study. Eight patients underwent the GnRH stimulation test. GnRH...

The effectiveness of the first Iranian made gonadotropin releasing hormone analogue, [D-Ala6des-Gly10] GnRH ethylamide, alone or in combination with domperidone, a dopamine antagonist on spawningrate, latency period, working fecundity and embryo viability in common carp, Cyprinus carpio, was investigated.Fifty two fish were divided into 5 groups and treated intrapretoneally as...

BACKGROUND Myomectomy has potential risks of complications. To reduce these risks, medical pre-treatment can be applied to reduce fibroid size and thereby potentially decrease intra-operative blood loss, the need for blood transfusion and emergency hysterectomy. The aim of this systematic review and meta-analysis is to study the effectiveness of medical pre-treatment with Gonadotropin-releasing...

Utero-ovarian arterial blood flow and hormonal profile were evaluated in 20 patients with polycystic ovary syndrome (PCOS) and in 22 patients with normal menstrual cycle (NMC) undergoing in-vitro fertilization (IVF) treatment. In this controlled prospective clinical study the vascular impedance in the utero-ovarian arteries was measured in both groups on days 4, 13, 22 [introduction of gonadotr...

The effectiveness of two kinds of dopamine antagonist (DA), metoclopramide (Met) and domperidone (Dom) combined with the gonadotropin releasing hormone analogue (D-Ala6, Des Gly10 ethylamide) GnRHa was assayed on the ovulation success, latency period, ovulation index (OI) and fertilization success of kutum, Rutilus frisii kutum (Kamenskii, 1901). Brood fish were injected intra-peritoneally as f...

In this study, the benefits of using the first Iranian made GnRHa[D-Ala6 des Gly10] mGnRH ethylamide, to induce spermiation in male rainbow trout, Oncorhynchus mykiss, were evaluated, In addition, its effect on acceleration and synchronization, quality and quantity of milt and the plasma Testosterone (T) fluctuations were examined. For these purposes, 40 non-spermiating male rainbow trouts were...

Gonadotropin-releasing hormone agonist (GnRHa) peptide drugs including leuprolide and deslorelin have been successfully used for decades in humans, domestic animals, free-ranging wildlife and animals in zoological facilities, and more recently in avian and exotic companion animals. Typical uses for GnRHa include reproductive stimulation, reproductive suppression (contraception or hormonerespons...